mix start year high
expect in-focu
roughli in-lin quarter without hiccup
rev y/i est
consensu organ sale growth vs estimate guid driven
diagnost dx segment core growth partial off-set growth
vs est discoveri analyt solut segment da sale
da impact academ govern biz due chiefli export
approv delay relat us govern shutdown revenue hit well timing-
relat appli market weak eu china w/ confid return msd
growth despit tougher comp later year dx strength broad-bas
mostli driven reproduct health genom servic fx sale in-lin
estimate adj gm vs estimate adj opm expand
y/i estimate due better product dx
oper leverag adj ep vs guide/street estimate
ticker announc acquisit cisbio bioassay assay servic
provid today annual sale margin
expect cisbio contribut adj ep guid
came sale w/ core growth includ tailwind
time relat rais sale ep guid
respect primarili driven deal reiter organ sale growth
yoy opm expans impli signific ramp-up well
acceler hit previous discuss target hsd core sale growth
opm might help growth cannabi reproduct
health appli genom think outlook doabl despit
tougher comp remain seen vanadi deliv euroimmun continu
current pace
updat estim stay neutral
reiter neutral rate po await clariti pki new
growth profil beyond adjust revenu est
lower ep estimate given better visibl margin trend
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart waltham massachusett
found diversifi
provid scientif instrument consum
servic address basic appli
research well signific global health
safeti issu includ matern fetal health
food safeti environment monitor today
compani oper two segment
environment
diversifi provid
scientif instrument consum servic
think compani tact piec
togeth numer acquir asset sinc
form uniqu comprehens solut
custom nich market posit
portfolio transform improv
growth profil believ compani still
face near-term headwind share
like rang bound
po base ep estim in-lin compani
broader lst diagnost peer group multipl signific premium
histor multipl due improv core growth margin think
multipl appropri given on-going oper improv improv
growth profil compani
upsid risk po better expect organ sale growth margin
expans faster uptak new product capit deploy option
acquisit compani
downsid risk competit execut integr risk weaker macro
environ fx swing fund cut slower expect uptak new
product regulatori risk reiter neutral rate
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
